Pertuzumab

Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

Product Specifications

CAS Number

[380610-27-5]

UNSPSC

12352203

Target

EGFR

Type

Inhibitory Antibodies

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Pertuzumab.html

Purity

99.80

Solubility

H2O

Smiles

[Pertuzumab]

Molecular Weight

(145.44 kDa)

References & Citations

[1]Nahta R, et al. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survivalof breast cancer cells. Cancer Res. 2004 Apr 1;64 (7) :2343-6.|[2]Scheuer W, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009 Dec 15;69 (24) :9330-6.